BATF2 and glioblastoma: Receiver Operating Characteristic (ROC) analysis showed that BATF2+EV detection in plasma showed an Ander Under the Curve (AUC) of 0.8576 (95% CI: 0.7450–0.9703) in stage I–II GBM vs. healthy donors, an AUC of 0.9653 (95% CI: 0.9147–1.016) in stage III–IV GBM vs. healthy donors, and an AUC of 0.7708 (95% CI: 0.6357–0.9059) in stage I–II GBM vs. stage III–IV GBM (Fig. 6E).